IMD3 Antibody

What is the IMD-3 antibody and what is its target?

IMD-3 is a mouse monoclonal antibody clone that targets c-Myc (v-myc myelocytomatosis viral oncogene homolog). This antibody specifically recognizes the human c-Myc protein and has been validated to show no cross-reactivity with other proteins. It belongs to the mouse IgG isotype and is primarily used for detecting c-Myc expression in human samples .

The c-Myc protein is a critical transcription factor involved in cell proliferation, apoptosis, and cellular transformation, making IMD-3 antibody an important tool in cancer research, developmental biology, and cellular signaling studies.

What detection applications is the IMD-3 antibody validated for?

The IMD-3 antibody has been validated for multiple experimental applications:

This validation ensures researchers can reliably use IMD-3 for detecting c-Myc across multiple experimental contexts, particularly in human samples .

What are the proper reconstitution and storage guidelines for optimal IMD-3 antibody performance?

For optimal performance, IMD-3 antibody should be reconstituted with either 1.2% sodium acetate or neutral PBS. When using 1ml of PBS, the resulting antibody concentration will be 100μg/ml . This standardized concentration facilitates consistent experimental design and reproducible results.

For storage considerations, researchers should follow these guidelines:

• Store at -20°C for long-term storage

• Avoid repeated freeze-thaw cycles

• Working aliquots can be prepared and stored at 4°C for short-term use

• Once reconstituted, use within 1-2 months for optimal activity

How should researchers design Western blot protocols using IMD-3 antibody?

When designing Western blot protocols with IMD-3 antibody, researchers should consider:

• Sample preparation: Use standard RIPA or NP-40 lysis buffers with protease inhibitors

• Gel percentage: 10-12% SDS-PAGE gels are optimal for resolving c-Myc (approximately 57-62 kDa)

• Transfer conditions: Semi-dry or wet transfer systems both work effectively

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute IMD-3 antibody to working concentration (typically 1:500-1:2000) in blocking buffer

• Incubation: Overnight at 4°C for optimal signal-to-noise ratio

• Detection system: HRP-conjugated anti-mouse secondary antibody followed by enhanced chemiluminescence

For reliable c-Myc detection, researchers should include positive controls such as cell lines known to express high levels of c-Myc (e.g., many cancer cell lines) .

What are the key considerations for immunohistochemistry using IMD-3 antibody?

For successful IHC-P applications with IMD-3 antibody, researchers should:

• Tissue fixation: Use 10% neutral buffered formalin fixation (optimal fixation time: 12-24 hours)

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is recommended

• Endogenous peroxidase blocking: 3% H₂O₂ in methanol for 10-15 minutes

• Antibody dilution: Typically 1:100-1:500 in antibody diluent

• Incubation time: 1-2 hours at room temperature or overnight at 4°C

• Detection system: HRP-conjugated anti-mouse secondary antibody and DAB substrate

• Counterstaining: Hematoxylin for nuclear visualization

Nuclear staining pattern should be expected for c-Myc detection, and researchers should include both positive and negative control tissues to validate staining specificity .

How does epitope specificity affect experimental design when using IMD-3 antibody?

Understanding the epitope specificity of IMD-3 is crucial for experimental design. While the exact epitope of IMD-3 isn't specified in the available data, researchers should consider:

• Epitope accessibility: The conformation of c-Myc in different experimental contexts can affect antibody binding

• Protein interactions: Protein-protein interactions might mask the epitope recognized by IMD-3

• Post-translational modifications: Modifications near the epitope may influence antibody binding affinity

Researchers can utilize Surface Plasmon Resonance (SPR) or ELISA techniques to assess binding characteristics and determine the equilibrium dissociation constant, which provides quantitative information about binding affinity . This information is valuable for optimizing experimental conditions.

What analytical techniques are recommended for comprehensive characterization of IMD-3 antibody?

For thorough characterization of IMD-3 antibody, researchers should employ multiple complementary techniques:

• Reversed-Phase Liquid Chromatography (RPLC): Effective for evaluating protein variations from chemical reactions or post-translational modifications, providing high resolution analysis of antibody integrity

• Surface Plasmon Resonance (SPR): Enables real-time measurement of binding kinetics, including:

  • Association rate (k₁)

  • Dissociation rate (k₋₁)

  • Equilibrium dissociation constant (KD)
    This technique helps determine epitope specificity and active concentration required for binding

• Enzyme-Linked Immunosorbent Assay (ELISA): Complementary to SPR for determining:

  • Affinity

  • Avidity

  • Immunoreactivity
    Both ELISA and SPR provide consistent results for antibody-antigen complex characterization

• Mass Spectrometry: For detailed structural analysis, identifying:

  • Post-translational modifications

  • Sequence variations

  • Potential degradation products

How can researchers assess and mitigate potential cross-reactivity of IMD-3 antibody?

To assess and minimize cross-reactivity:

• Perform knockout/knockdown validation: Test the antibody on samples with c-Myc knockdown or knockout to confirm specificity

• Peptide competition assay: Pre-incubate the antibody with purified c-Myc peptide before application to samples; specific binding should be blocked

• Western blot analysis across multiple cell/tissue types: Look for bands only at the expected molecular weight

• Immunoprecipitation followed by mass spectrometry: Identify all proteins pulled down by the antibody

• Testing on recombinant c-Myc family members: Evaluate potential cross-reactivity with related proteins (e.g., N-Myc, L-Myc)

Although the product information indicates no cross-reactivity with other proteins , independent validation is still recommended as experimental conditions may vary.

What are common causes of inconsistent results when using IMD-3 antibody?

Inconsistent results with IMD-3 antibody may stem from several factors:

• Antibody degradation: Monoclonal antibodies can degrade over time, especially with improper storage or repeated freeze-thaw cycles

• Variation in c-Myc expression levels: c-Myc is highly regulated and its expression can vary significantly with:

  • Cell cycle phase

  • Culture conditions

  • Stress responses

  • Sample handling procedures

• Post-translational modifications: c-Myc undergoes multiple modifications that may affect epitope accessibility:

  • Phosphorylation

  • Ubiquitination

  • Acetylation

  • Glycosylation

• Technical variations in sample preparation: Differences in:

  • Fixation time and procedure

  • Buffer composition

  • Protein extraction methods

  • Antigen retrieval conditions

• Detection system sensitivity: Variations in:

  • Secondary antibody quality

  • Substrate freshness

  • Imaging parameters

How can researchers validate IMD-3 antibody lot-to-lot consistency?

To ensure experimental reproducibility across different antibody lots, researchers should:

• Perform side-by-side comparison using:

  • Western blot with standard positive control samples

  • ELISA with known quantities of recombinant c-Myc

  • IHC-P on standardized tissue sections

• Document key performance metrics:

  Parameter	Measurement Method	Acceptable Variation
  Binding affinity	SPR or ELISA	±20% KD value
  Specificity	Western blot band pattern	Same MW target band
  Sensitivity	Limit of detection assay	±1 dilution factor
  Signal-to-noise ratio	Image analysis of blots/IHC	±15%

• Implement a reference standard system: Maintain aliquots of a well-characterized antibody lot to serve as a benchmark for testing new lots

What analytical techniques can detect and quantify potential degradation of IMD-3 antibody?

Several analytical techniques are effective for monitoring IMD-3 antibody stability and detecting degradation:

• Size Exclusion Chromatography (SEC): Detects aggregation, fragmentation, and changes in molecular weight

• Reversed-Phase Liquid Chromatography (RPLC): Identifies chemical modifications and degradation products with high resolution

• Capillary Electrophoresis (CE): Assesses charge heterogeneity that may result from deamidation or other modifications

• Differential Scanning Calorimetry (DSC): Evaluates thermal stability and conformational changes

• Dynamic Light Scattering (DLS): Monitors aggregation states

These analytical methods can be used to establish quality control metrics for antibody preparations, ensuring research reproducibility and reliability .

How can IMD-3 antibody be incorporated into advanced multiplexed imaging techniques?

Researchers can incorporate IMD-3 antibody into multiplexed imaging workflows through:

• Sequential multiplex immunofluorescence:

  • Apply IMD-3 primary antibody followed by fluorophore-conjugated secondary

  • Image the tissue

  • Strip antibodies using elution buffer (e.g., glycine pH 2.5 or commercial antibody stripping solutions)

  • Repeat with additional antibodies for other targets

• Spectral unmixing approaches:

  • Use spectrally distinct fluorophores for each antibody

  • Apply mathematical algorithms to separate overlapping emission spectra

• Tyramide signal amplification (TSA):

  • Allows use of multiple primary antibodies from the same species

  • Provides signal amplification for enhanced sensitivity

  • Enables permanent signal retention after antibody stripping

When incorporating IMD-3 into these workflows, researchers should validate that antibody stripping doesn't affect tissue morphology or antigen preservation for subsequent staining rounds.

What considerations are important when using IMD-3 antibody for studying c-Myc in complex biological systems?

When studying c-Myc in complex biological systems with IMD-3 antibody, researchers should address:

• Temporal dynamics of c-Myc expression:

  • c-Myc has a short half-life (~20-30 minutes)

  • Expression levels change rapidly in response to stimuli

  • Timing of sample collection is critical for reproducible results

• Spatial heterogeneity:

  • c-Myc expression varies between different cell types within a tissue

  • Single-cell techniques may be necessary to resolve heterogeneous expression

  • Consider complementing bulk analyses with spatial techniques

• Context-dependent protein interactions:

  • c-Myc functions within protein complexes that vary by cell type and condition

  • These interactions may affect IMD-3 epitope accessibility

  • Co-immunoprecipitation can help identify relevant interaction partners

• Integration with functional readouts:

  • Correlate c-Myc detection with downstream gene expression

  • Combine with proliferation markers to assess functional consequences

  • Consider multiplexed approaches to capture pathway activities

These considerations help ensure that IMD-3 antibody applications yield biologically meaningful data about c-Myc function in complex systems.